Carnegie Lake Advisors LLC Has $699,000 Stock Position in Merck & Co., Inc. $MRK

Carnegie Lake Advisors LLC reduced its position in shares of Merck & Co., Inc. (NYSE:MRK) by 7.8% during the second quarter, Holdings Channel reports. The institutional investor owned 8,832 shares of the company’s stock after selling 750 shares during the period. Carnegie Lake Advisors LLC’s holdings in Merck & Co., Inc. were worth $699,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in MRK. Little House Capital LLC increased its position in Merck & Co., Inc. by 1.2% during the second quarter. Little House Capital LLC now owns 25,236 shares of the company’s stock worth $1,998,000 after buying an additional 308 shares in the last quarter. Semus Wealth Partners LLC lifted its position in shares of Merck & Co., Inc. by 8.2% in the first quarter. Semus Wealth Partners LLC now owns 5,039 shares of the company’s stock valued at $452,000 after acquiring an additional 382 shares in the last quarter. Longfellow Investment Management Co. LLC boosted its stake in shares of Merck & Co., Inc. by 20.4% during the first quarter. Longfellow Investment Management Co. LLC now owns 19,376 shares of the company’s stock valued at $1,739,000 after acquiring an additional 3,282 shares during the last quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH boosted its stake in shares of Merck & Co., Inc. by 9.8% during the second quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 888,415 shares of the company’s stock valued at $70,327,000 after acquiring an additional 79,529 shares during the last quarter. Finally, Amplius Wealth Advisors LLC increased its position in Merck & Co., Inc. by 117.4% during the 2nd quarter. Amplius Wealth Advisors LLC now owns 6,165 shares of the company’s stock worth $488,000 after purchasing an additional 3,329 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on MRK. Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Morgan Stanley raised their target price on shares of Merck & Co., Inc. from $98.00 to $100.00 and gave the stock an “equal weight” rating in a research report on Monday, November 3rd. Citigroup started coverage on shares of Merck & Co., Inc. in a research note on Monday, October 13th. They issued a “neutral” rating and a $95.00 target price for the company. Wells Fargo & Company cut their price target on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a report on Wednesday, July 30th. Finally, Berenberg Bank lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating and reduced their price target for the stock from $100.00 to $90.00 in a research note on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $104.47.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $86.34 on Friday. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $215.66 billion, a P/E ratio of 13.30, a PEG ratio of 0.95 and a beta of 0.34. The firm has a fifty day moving average of $84.59 and a 200-day moving average of $82.04. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $105.07.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Thursday, October 30th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.36 by $0.22. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. The firm had revenue of $17.28 billion during the quarter, compared to analysts’ expectations of $17 billion. During the same period in the prior year, the company earned $1.57 EPS. The firm’s revenue was up 3.7% on a year-over-year basis. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. As a group, analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current year.

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP David Michael Williams sold 8,614 shares of the stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $83.59, for a total value of $720,044.26. Following the completion of the sale, the executive vice president owned 24,578 shares in the company, valued at approximately $2,054,475.02. This trade represents a 25.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.13% of the stock is owned by insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.